Results 91 to 100 of about 32,701 (226)

Mass Spectrometry Structural Proteomics Enabled by Limited Proteolysis and Cross‐Linking

open access: yesMass Spectrometry Reviews, EarlyView.
ABSTRACT The exploration of protein structure and function stands at the forefront of life science and represents an ever‐expanding focus in the development of proteomics. As mass spectrometry (MS) offers readout of protein conformational changes at both the protein and peptide levels, MS‐based structural proteomics is making significant strides in the
Haiyan Lu   +4 more
wiley   +1 more source

Neutrophil Modulation in Alpha-1 Antitrypsin Deficiency.

open access: yesChronic obstructive pulmonary diseases, 2020
Neutrophils have been implicated in the pathogenesis of alpha-1 antitrypsin deficiency (AATD) since the first descriptions of the disease. Neutrophil proteinases can cause all lung manifestations of AATD, from small airways destruction, to emphysema, to ...
E. Sapey
semanticscholar   +1 more source

Reduction in Synaptic Vesicle Protein Abundance but Increased Amounts of Nsg2 and Lpcat1 in Cerebral Cortices Without the Endosomal SNARE Proteins Vti1a and Vti1b

open access: yesPROTEOMICS, EarlyView.
ABSTRACT Absence of the endosomal SNAREs vti1a and vti1b results in perinatal death and severe neuronal phenotypes in mice, while lack of one of these proteins results in minor phenotypes. Proteomic differences were investigated to obtain a deeper insight into processes in which vti1a and vti1b are involved.
Julia Gottschalk   +4 more
wiley   +1 more source

Alpha 1 antitrypsin deficiency in non cystic fibrosis bronchiectasis

open access: yesEgyptian Journal of Chest Disease and Tuberculosis, 2013
Setting: It is important to identify manifestations of alpha1-antitrypsin deficiency (A1ATD) in bronchiectasis to improve care and outcome in these patients.
Mohamed Shahat Badawy   +2 more
doaj   +1 more source

The Alpha‐1 Pi*MZ Genotype Is an Independent Risk Factor for Hepatocellular Carcinoma Development in Patients With ACLD

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Alpha‐1 antitrypsin deficiency is a genetic disease that affects the lungs and the liver. The role of the heterozygous genetic defect in the development of liver cancer in patients with cirrhosis is unclear. Our study found that carrying the Pi*MZ genotype increases the risk of developing liver cancer.
Lorenz Balcar   +18 more
wiley   +1 more source

Alpha-1 antitrypsin deficiency and Pi*S and Pi*Z SERPINA1 variants are associated with asthma exacerbations

open access: yesPulmonology
Introduction and objectives Asthma is a chronic inflammatory disease of the airways. Asthma patients may experience potentially life-threatening episodic flare-ups, known as exacerbations, which may significantly contribute to the asthma burden. The Pi*S
Elena Martín-González   +27 more
doaj   +1 more source

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
We conducted a nationwide, multicenter cohort study using a target trial emulation framework to compare baclofen and acamprosate in patients with compensated alcohol‐associated cirrhosis. After matching, baclofen initiation was associated with a higher 1‐year risk of major adverse liver outcomes, driven primarily by hepatic encephalopathy, particularly
Yee Hui Yeo   +13 more
wiley   +1 more source

The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency: The Association Between Diagnostic Delay and Worsened Clinical Status

open access: yesRespiratory care, 2019
BACKGROUND: Alpha-1 antitrypsin deficiency is frequently underrecognized. Individuals with symptoms often experience long diagnostic delays. Although a delayed diagnosis is logically presumed to be associated with adverse effects, confirmatory evidence ...
V. Tejwani   +4 more
semanticscholar   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos   +16 more
wiley   +1 more source

Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications

open access: yesInternational Journal of COPD, 2018
Kenneth R Chapman,1 Joanna Chorostowska-Wynimko,2 A Rembert Koczulla,3 Ilaria Ferrarotti,4 Noel G McElvaney5 1Department of Medicine, University of Toronto, Toronto, ON, Canada; 2Department of Genetics and Clinical Immunology, National Institute of ...
Chapman KR   +4 more
doaj  

Home - About - Disclaimer - Privacy